IAP proteins as targets for drug development in oncology
about
Modulation of Protein-Protein Interactions for the Development of Novel TherapeuticsSmall-molecule SMAC mimetics as new cancer therapeuticsDeath-defining immune responses after apoptosisAberrant splicing and drug resistance in AMLTumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategiesInducing death in tumor cells: roles of the inhibitor of apoptosis proteins.Small-molecule inhibitors of protein-protein interactions: progressing toward the reality.Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study.Prognostic value of survivin in patients with non-Hodgkin's lymphoma: a meta-analysis.Dual targeting of microtubule and topoisomerase II by α-carboline derivative YCH337 for tumor proliferation and growth inhibition.The SMAC mimetic BV6 sensitizes colorectal cancer cells to ionizing radiation by interfering with DNA repair processes and enhancing apoptosis.Curcumin Induces Pancreatic Adenocarcinoma Cell Death Via Reduction of the Inhibitors of ApoptosisIntrinsic and chemo-sensitizing activity of SMAC-mimetics on high-risk childhood acute lymphoblastic leukemia.Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study.Molecular mechanisms and anti-cancer aspects of the medicinal phytochemicals rocaglamides (=flavaglines).Targeting the inhibitor of Apoptosis Protein BIR3 binding domains.Mitochondria-mediated apoptosis in mammals.Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities.Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Apoptotic and autophagic pathways with relevant small-molecule compounds, in cancer stem cells.miRNAs and ovarian cancer: a miRiad of mechanisms to induce cisplatin drug resistance.The SMAC mimetic BV6 induces cell death and sensitizes different cell lines to TNF-α and TRAIL-induced apoptosis.Regulating the balance between necroptosis, apoptosis and inflammation by inhibitors of apoptosis proteins.Experimental study of a novel tumstatin on C6 brain glioma in vitro.Prognostic significance of survivin in breast cancer: meta-analysis.Cross-Linking Mass Spectrometry: An Emerging Technology for Interactomics and Structural Biology.Mithramycin A Enhances Tumor Sensitivity to Mitotic Catastrophe Resulting From DNA Damage.Inhibitor of apoptosis proteins, NAIP, cIAP1 and cIAP2 expression during macrophage differentiation and M1/M2 polarization.Cytoplasmic FLIP(S) and nuclear FLIP(L) mediate resistance of castrate-resistant prostate cancer to apoptosis induced by IAP antagonists
P2860
Q26775356-470B995E-3344-4B00-80DC-EDE6BE8D280AQ26864204-41676BC2-D592-4856-A109-91FC039E1F7AQ27010494-E77A13CE-24FC-451A-B80A-8101CD76FF38Q28076011-B93EEE8B-0E0F-4BC9-881A-4DA875D27836Q28085631-92B0FA32-4489-46CD-BB6B-A4171961802CQ33632016-AD14771D-5603-479C-B383-FE9B6584E551Q34263719-DE083071-3125-4909-B99A-ED83411A91E9Q35193374-6C131BCF-F743-4B22-B910-961B39EA3F98Q35679467-7758C4E7-397C-4BC4-995B-95F3A0F6DE92Q35832271-00EB09C1-22C5-48D5-9808-236A5147DE3EQ36069954-C299DD52-F3FC-42D5-A8EC-11C7B0E24971Q36373429-83CF50F1-6296-4A05-B772-0F53D15FB9ECQ36751715-9137EB56-61A5-4AF1-97D5-C5B1A4DF8422Q37267506-8620E0BF-E78B-4ED0-B106-C609AD8C649EQ38217477-87540BFD-DA90-4AB9-998A-B5622B3AB51EQ38226672-23EA1B4B-800C-4AE5-8E8A-67E543CA5749Q38235124-EAE89BB1-5305-4C36-A184-380454BB7726Q38252591-4CBDCCF8-4A7F-455D-9480-71863D17F967Q38484840-FBCB59A1-A924-4AFB-9610-6EFCC2DF5F34Q38503469-F82359B9-10B1-4CA6-81B5-8D0220312627Q38633144-5DDEA7D8-CB99-4592-B9BD-63A1D0A19667Q38755349-0B8292F0-8CD9-43E7-AD9B-CF176E72523BQ39025072-BF12DA2B-D474-48A2-8C95-34CB8BF3CCB4Q41612854-1DD181A2-7765-421D-BF3D-AFAB2C97EE6DQ43464457-BA46F835-2390-4F3F-8CB4-72C138BF787DQ46525686-E25D9F0E-1D25-4C3A-A0F3-630A279B92A8Q47382418-25BE1369-4FFB-4BE3-99C6-D07A4D82FCEAQ52666797-762B5E33-F2DB-4015-83C5-826D882F67E6Q57801734-9E86E1FD-BE21-4786-8C87-96D6EFBFE205
P2860
IAP proteins as targets for drug development in oncology
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
IAP proteins as targets for drug development in oncology
@en
IAP proteins as targets for drug development in oncology.
@nl
type
label
IAP proteins as targets for drug development in oncology
@en
IAP proteins as targets for drug development in oncology.
@nl
prefLabel
IAP proteins as targets for drug development in oncology
@en
IAP proteins as targets for drug development in oncology.
@nl
P2860
P356
P1476
IAP proteins as targets for drug development in oncology
@en
P2093
Jean Berthelet
Valérie Glorian
P2860
P304
P356
10.2147/OTT.S33375
P407
P50
P577
2013-09-16T00:00:00Z